Literature DB >> 12634380

Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein.

X Zhan1, K S Slobod, S Surman, S A Brown, T D Lockey, C Coleclough, P C Doherty, J L Hurwitz.   

Abstract

Single-envelope human immunodeficiency virus (HIV) vaccines have been studied for more than a decade, with some successes in homologous challenge experiments in nonhuman primates but with no clear successes in clinical trials. To gain insight into the breadth of the immunity elicited by such vaccines, we have dissected the T-helper cell response of C57BL/6 mice to an individual, molecularly cloned envelope protein. Here, we report that T-helper cells responsive to HIV type 1 1035 envelope are very highly restricted in C57BL/6 animals: seven different hybridomas recovered from five separate mice recognized the same peptide, PKVSFEPIPIHYCAP, located in the C2 region of gp120. Three of these hybridomas were tested on a natural variant of the peptide but failed to respond. A more extensive analysis of whole splenic populations from other C57BL/6 mice immunized with the 1035 envelope reproducibly confirmed that the gp120-specific T-helper response was almost exclusively focused on a single epitope. We conclude that single-envelope vaccines may frequently fail to provoke an immune response sufficiently diverse to recognize variant sequences among circulating HIV. The results encourage the inclusion of more than one envelope in future vaccines to enhance the potential diversity and respective surveillance capacities of responding T-helper cell populations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12634380      PMCID: PMC150625          DOI: 10.1128/jvi.77.7.4231-4236.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

Review 1.  T lymphocyte responses in HIV-1 infection: implications for vaccine development.

Authors:  C Brander; B D Walker
Journal:  Curr Opin Immunol       Date:  1999-08       Impact factor: 7.486

Review 2.  The HIV vaccine pipeline, from preclinical to phase III.

Authors:  A M Schultz; J A Bradac
Journal:  AIDS       Date:  2001       Impact factor: 4.177

3.  Structural basis for helper T-cell and antibody epitope immunodominance in bacteriophage T4 Hsp10. Role of disordered loops.

Authors:  Guixiang Dai; Stephanie Carmicle; N Kalaya Steede; Samuel J Landry
Journal:  J Biol Chem       Date:  2001-10-15       Impact factor: 5.157

4.  Superantigen enhancement of specific immunity: antibody production and signaling pathways.

Authors:  Barbara A Torres; George Q Perrin; Mustafa G Mujtaba; Prem S Subramaniam; Amy K Anderson; Howard M Johnson
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

5.  Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.

Authors:  T D Lockey; K S Slobod; T E Caver; S D'Costa; R J Owens; H M McClure; R W Compans; J L Hurwitz
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

6.  Allocation of helper T-cell epitope immunodominance according to three-dimensional structure in the human immunodeficiency virus type I envelope glycoprotein gp120.

Authors:  G Dai; N K Steede; S J Landry
Journal:  J Biol Chem       Date:  2001-09-10       Impact factor: 5.157

7.  A highly sensitive single-cell assay detects T-helper cell responses missed by conventional interleukin-2-based methods.

Authors:  Sherri Surman; Julia L Hurwitz
Journal:  J Immunol Methods       Date:  2002-02-01       Impact factor: 2.303

8.  Comprehensive screening for human immunodeficiency virus type 1 subtype-specific CD8 cytotoxic T lymphocytes and definition of degenerate epitopes restricted by HLA-A0207 and -C(W)0304 alleles.

Authors:  Jeffrey R Currier; Mark deSouza; Penprapa Chanbancherd; Wendy Bernstein; Deborah L Birx; Josephine H Cox
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  Qualitative and quantitative studies of antigen-presenting cell function by using I-A-expressing L cells.

Authors:  R I Lechler; M A Norcross; R N Germain
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition.

Authors:  J W Kappler; B Skidmore; J White; P Marrack
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

View more
  8 in total

1.  UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.

Authors:  Bart G Jones; Robert E Sealy; Xiaoyan Zhan; Pamela J Freiden; Sherri L Surman; James L Blanchard; Julia L Hurwitz
Journal:  Vaccine       Date:  2012-03-14       Impact factor: 3.641

2.  Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen.

Authors:  Eric A Weaver; Zhongjing Lu; Zenaido T Camacho; Fatiha Moukdar; Hua-Xin Liao; Ben-Jiang Ma; Mark Muldoon; James Theiler; Gary J Nabel; Norman L Letvin; Bette T Korber; Beatrice H Hahn; Barton F Haynes; Feng Gao
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Simon Beddows; Norbert Schülke; Marc Kirschner; Kelly Barnes; Michael Franti; Elizabeth Michael; Thomas Ketas; Rogier W Sanders; Paul J Maddon; William C Olson; John P Moore
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Major histocompatibility complex class II molecule-human immunodeficiency virus peptide analysis using a microarray chip.

Authors:  Simani Gaseitsiwe; Davide Valentini; Raija Ahmed; Shahnaz Mahdavifar; Isabelle Magalhaes; Johannes Zerweck; Mike Schutkowski; Emmanuel Gautherot; Felix Montero; Anneka Ehrnst; Marie Reilly; Markus Maeurer
Journal:  Clin Vaccine Immunol       Date:  2009-02-18

5.  Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins.

Authors:  Robert E Sealy; Bart G Jones; Sherri L Surman; Kristen Branum; Nanna M Howlett; Patricia M Flynn; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2015-11-06       Impact factor: 2.257

Review 6.  Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine.

Authors:  Robert Sealy; Karen S Slobod; Patricia Flynn; Kristen Branum; Sherri Surman; Bart Jones; Pamela Freiden; Timothy Lockey; Nanna Howlett; Julia L Hurwitz
Journal:  Int Rev Immunol       Date:  2009       Impact factor: 5.311

7.  Antigen structure influences helper T-cell epitope dominance in the human immune response to HIV envelope glycoprotein gp120.

Authors:  Denise Mirano-Bascos; Magdalena Tary-Lehmann; Samuel J Landry
Journal:  Eur J Immunol       Date:  2008-05       Impact factor: 5.532

8.  Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary?

Authors:  Karen S Slobod; Chris Coleclough; Scott A Brown; John Stambas; Xiaoyan Zhan; Sherri Surman; Bart G Jones; Amy Zirkel; Pamela J Freiden; Brita Brown; Robert Sealy; Mattia Bonsignori; Julia L Hurwitz
Journal:  AIDS Res Ther       Date:  2005-04-28       Impact factor: 2.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.